| NDC Code | 43742-0992-1 |
|---|
| Package Description | 30 mL in 1 BOTTLE, DROPPER (43742-0992-1) |
|---|
| Product NDC | 43742-0992 |
|---|
| Product Type Name | HUMAN OTC DRUG |
|---|
| Proprietary Name | Ent Support |
|---|
| Non-Proprietary Name | Pulsatilla (vulgaris), Euphorbium Officinarum, Luffa Operculata, Mercurius Iodatus Ruber, Argentum Nitricum, Hepar Sulphuris Calcareum, Influenzinum (2016-2017), Sinusitisinum, Aspergillus Niger, Candida Albicans, Gallicum Acidum, Mucor Racemosus, Mutabile Bacillus (bach) |
|---|
| Dosage Form | LIQUID |
|---|
| Usage | ORAL |
|---|
| Start Marketing Date | 20170314 |
|---|
| End Marketing Date | 20220726 |
|---|
| Marketing Category Name | UNAPPROVED HOMEOPATHIC |
|---|
| Manufacturer | Deseret Biologicals, Inc. |
|---|
| Substance Name | ASPERGILLUS NIGER VAR. NIGER; CALCIUM SULFIDE; CANDIDA ALBICANS; ESCHERICHIA COLI; EUPHORBIA RESINIFERA RESIN; GALLIC ACID MONOHYDRATE; INFLUENZA A VIRUS A/CALIFORNIA/7/2009 X-181 (H1N1) HEMAGGLUTININ ANTIGEN (PROPIOLACTONE INACTIVATED); INFLUENZA A VIRUS A/HONG KONG/4801/2014 X-263B (H3N2) HEMAGGLUTININ ANTIGEN (PROPIOLACTONE INACTIVATED); INFLUENZA B VIRUS B/BRISBANE/60/2008 HEMAGGLUTININ ANTIGEN (PROPIOLACTONE INACTIVATED); LUFFA OPERCULATA FRUIT; MERCURIC IODIDE; MUCOR RACEMOSUS; PULSATILLA VULGARIS; SILVER NITRATE; SINUSITISINUM |
|---|
| Strength | 10; 10; 10; 30; 6; 10; 11; 11; 11; 6; 8; 10; 2; 10; 17 |
|---|
| Strength Unit | [hp_C]/mL; [hp_X]/mL; [hp_C]/mL; [hp_C]/mL; [hp_X]/mL; [hp_C]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_C]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL |
|---|
| Pharmacy Classes | Actively Acquired Immunity [PE], Actively Acquired Immunity [PE], Allergens [CS], Allergens [CS], Allergens [CS], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Cell-mediated Immunity [PE], Fungal Proteins [CS], Fungal Proteins [CS], Fungal Proteins [CS], Inactivated Influenza A Virus Vaccine [EPC], Inactivated Influenza B Virus Vaccine [EPC], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased Histamine Release [PE], Increased IgG Production [PE], Increased IgG Production [PE], Increased IgG Production [PE], Influenza Vaccines [CS], Influenza Vaccines [CS], Non-Standardized Fungal Allergenic Extract [EPC], Non-Standardized Fungal Allergenic Extract [EPC], Non-Standardized Fungal Allergenic Extract [EPC], Vaccines, Inactivated [CS], Vaccines, Inactivated [CS] |
|---|